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Title: 
Service Users’ Experiences of Using Community Pharmacies to Access 
Treatment for Opioid Dependency 
Abstract 
Aim: 
To explore experiences of service users attending a community pharmacy to receive opiate 
replacement therapy (ORT). 
Method: 
Qualitative study involving seven focus groups undertaken within care centres and prison 
educational centre in Tayside, Scotland using 41 participants.  Thematic analysis undertaken 
of experiences of different groups of service users and carers. 
Results 
Participants described the social context surrounding attendance at community pharmacies. 
Their voices suggested that people prescribed ORT may be treated differently from others 
accessing care through pharmacies. Participants felt they experienced stigma and 
discriminatory practices in pharmacies, elsewhere within the healthcare environment, and 
more generally in society. Participants explained that the way services were organised in 
pharmacies often denied them the right to confidentiality. 
However, there were positive experiences of care. The discriminating factor between good 
and bad experiences was being treated with dignity and respect. 
Conclusion 
Participants readily identified examples of poor experiences and of stigma and 
discrimination, yet valued positive relationships with their pharmacy. Constructive attitudes of 
pharmacy staff and the ability to form positive relationships improved their experience. The 
social exclusion delivered through stigmatisation mitigates against delivery of a recovery 
agenda and contributes to health inequalities experienced by this marginalised group. 
  
Title:  
“Standing outside the Junkie Door” Service Users’ Experiences of Using 
Community Pharmacies to Access Treatment for Opioid Dependency 
Introduction 
Supervised consumption of Opioid Replacement Therapy (ORT) has been the mainstay of 
treatment for people who use heroin for some time 1.  Drug users have attended pharmacies 
in Scotland to receive supervised administration of replacement drugs since the early 1990s. 
The shared care arrangement, between prescribers, specialist drug treatment services and 
community pharmacies reduces diversion of methadone into the illicit market and increases 
access to this treatment 2.  However, across Europe, treatment is mostly conducted in 
outpatient settings, which can include specialist centres, general practitioners and low-
threshold facilities3. 
In practice, this means that service users attend a pharmacy on a daily or regular basis to 
receive doses of methadone or buprenorphine; this is intended to replace the consumption 
of heroin. The consumption of the ORT dose may be supervised, or handed to the service 
user to consume off premises 2.  It is estimated there are 376,136 “problem drug users” in 
the United Kingdom, and 133,112 people who inject drugs (PWID) 3. The European 
Monitoring Centre for Drugs and Drug Addiction (EMCDDA) defines PWIDs as “ever 
injectors” among people tested in drug service settings 5.  In Scotland, approximately 59,000 
people are identified as using drugs 6.  The number of opioid users prescribed treatment in 
2011/12 was estimated at 149,000 in England and Wales 7. An estimated figure Scotland 
would therefore be 22,224 8.  
There is strong evidence that ORT improves a range of important outcomes 9.  Longitudinal 
studies identify that ORT improves retention in treatment, reduces illicit use of substances 
and reduces levels of risk behaviours.  Reduced criminal activity and improved health and 
well-being have been reported 10, 11, 12, 13, 14, 15.  There is also evidence of a positive 
correlation between “treatment dose” (numbers of attendances) and outcome 16.  The 
contribution of supervised consumption to recovery may be double-edged: creating a daily 
structure and reducing use of other opiates, but preventing engagement in recovery activities 
such as paid work.  Supervised consumption is a central component of the United Kingdom 
policy framework 17. Policy makers may view long-term maintenance on ORT either as a 
positive step for harm-minimisation or as a barrier to achieving a drug-free lifestyle: moving 
ORT users to a drug-free lifestyle remains a challenge18. 
The success of ORT depends on engagement with services and adherence to therapy.  The 
Drug Misuse and Dependence: UK Guidelines on Clinical Management 17 (also known as 
the Orange Guide) states that directly supervised ORT by a professional for a period of time 
provides the best guarantee that the medicine is being taken as prescribed.  Supervised 
consumption as part of the recovery process may be protective and associated with a 
decrease in drug deaths and development of a therapeutic relationship.  The journey of 
recovery may mean the movement to unsupervised consumption over time 19. 
In practice, most ORT is delivered by community pharmacists and increasing numbers of 
pharmacies provide needle exchange services 20.  Pharmacists and dispensing staff are 
central to the provision of ORT 21. Service users therefore may have more contact with the 
pharmacist than any other healthcare worker 22. 
Despite growing evidence to support the delivery of therapeutic interventions through 
community pharmacies 23, there is evidence that outcomes obtained with ORT can be 
improved 24.  A partial explanation for poorer outcomes may lie in service users’ interactions 
within and around community pharmacy services 25, 26, 27, 28, 29.  Stigma, combined with a poor 
self image and apparent negative treatment may provoke negative behaviour and precipitate 
conflict 30. Pharmacists may be reluctant to deal with a group of clients who may sometimes 
be abusive or intoxicated and may shoplift 2 
Although pharmacy service provision is extensive, there is little contemporary research 
describing the nature of these interactions with service users, associated problems, or likely 
solutions.  This study was conducted to explore the current experiences of service users 
attending a community pharmacy and receiving ORT in Tayside, Scotland. 
Method 
The study was conducted within care centres and a prison educational centre as part of a 
local Public Health needs assessment. A focus group methodology was chosen to enable 
participants to share experiences within a supportive environment.  Utilisation of the group 
dynamic and involvement of participants in group discussions was employed to help manage 
impulsive behaviour and short attention span 31.  Effective management of these factors was 
believed to outweigh potential negative aspects of focus group approach including 
description of group normative experiences and the effect of inherent group hierarchies to 
suppress subordinate voices 32. 
Study documents were submitted to the East of Scotland Research Ethics Service, who 
confirmed this work did not require Ethical Approval.  Caldecott permission was gained to 
enable access to and analysis of patient information.  A topic guide was developed from 
evidence syntheses and refined during the study (Table1). 
Sampling: 
The study used a purposive sampling strategy to identify a diversity of likely views 33.  
Individuals were eligible for inclusion if they received ORT from a community pharmacy or 
were the carer of someone prescribed ORT.  We aimed to recruit around 40 participants. 
Recruitment focussed on the following variables:  
• Place of Residence –large urban / other urban / accessible small town 
• Service Users detained by the Criminal Justice System 
• Perspectives of male and female service users 
• Perspectives of peer mentors (service users at an advanced stage of recovery) 
The sampling strategy was formulated to enable a diversity of views to be obtained, at 
different places within the network of actors and technologies 34.  Carers were included in the 
groups, since ORT users experience long-term conditions at an earlier stage than the 
general population. 
Recruitment & consent: 
Potential contributors were identified through local support groups and care centres.  Each 
person completed a consent form prior to participation. The patient information sheet was 
explained to each group by the facilitator to assist those with poor health literacy.  
Data collection: 
Seven focus groups with 41 participants (Table 2) were undertaken by AR and KM. Sessions 
were open-ended and ranged from 70–100 minutes.  The first focus group served as an 
internal pilot to test the discussion guide.  The seventh focus group with peer mentors, was 
undertaken to provide perspective on the findings from this study. In the local service 
configuration, peer mentors are experienced service users who have received ORT for a 
number of years and are further along a recovery pathway: we listened to their reflections 
and perspectives on the themes that had emerged. 
Analysis: 
Data from each focus group were digitally recorded and transcribed verbatim. Both AR and 
KM undertook the coding and analysis (Box 1).  Analysis drew on the constant comparison 
method, which was operationalised within a general thematic approach 35. Analysis included 
five stages: familiarisation (reading and re-reading the transcripts), identifying a thematic 
framework (a key list of codes); applying the codes to the quotes in the transcripts; creating 
tables of quotes and comments to compare data across groups; mapping and integrating the 
key findings into a meaningful whole. Deviant cases were sought to identify opinions which 
modified or contradicted the analysis 36 
In our analysis we drew on the work of Duff who utilises Actor Network Theory to portray the 
assemblage of spaces, bodies and effects, to characterise the context of drug use as the 
interrelation of people and technology 37, 38. 
Results 
Service users were reflective about the circumstances that led to them receiving ORT from a 
pharmacy.  When asked about their experiences of attending a pharmacy, participants’ 
responses were often passionately voiced.  Focus group data demonstrated interactions 
between different actors and technologies: with pharmacy staff; members of the public; 
pharmacy premises and adjacent environments; the rules used by the pharmacy to manage 
demands and workload.  
Our analysis identified three key themes (Box 2). These are illustrated with quotes 
demonstrating typical or divergent responses. Quotes are labelled with participant number, 
sex and age. 
The social context surrounding ORT users 
Service users provided vivid descriptions of life on methadone. Participants followed a daily 
routine of attending pharmacies, obtaining money, and avoiding trouble (Box 3, Participant 
16).  Some service users reflected on their preoccupation with obtaining drugs, legal and 
illicit. They felt that the centrality of ORT in their life led to diminished horizons (Box 3, 
Participant 40).  The day-to-day reality of ORT use was one of continuous poverty: lack of 
money was a constant challenge; searching for enough money to pay for daily expenses; 
having bus money; the difficulties in maintaining employment (Box 3, Participant 20). 
The attraction of ORT waned over time. Some participants explained how methadone and 
drug use became less important to them and family life and employment increased in 
importance (Box 3, Participant 33).  Participants described how they changed their social 
networks to move away from drug use; they described the need for a ‘normal life’ (Box 3, 
Participant 18).   
The interaction with pharmacy service delivery 
Service users’ often had both positive and negative experiences of community pharmacies.  
Participants provided accounts of positive relationships and contributions to care but many 
examples of poor experiences and unpleasant relationships were described. 
Experience of stigma 
Participants described real and current experiences of stigma.  The idea that people would 
shun them was common. They felt set apart from other members of society (Box 4, 
Participant 18).  Service users sensed this treatment was unjust; other people had chronic 
conditions such as heart disease and diabetes, which were also self-inflicted, but were not 
discriminated against (Box 4, Participant 22).  People who abused prescription medication 
(benzodiazepines) were not treated as they were. Service users felt unfairly treated since 
they had chosen to change, through entering the ORT programme.  
Experience of discrimination 
Participants felt that use of a range of different practices within pharmacies caused a 
distinction between people picking up a methadone prescription and people picking up other 
prescriptions (Box 4, Participant 8). Discrimination was conveyed in numerous ways, 
including restricted attendance times and additional bureaucracy (Box 4, Participant 20).  In 
two focus groups, service users described how they were asked to leave young children 
outside the pharmacy.  The women’s group was particularly reflective on how they were 
treated differently and used the powerful metaphor of “Apartheid”. 
The use of a separate entrance or hatch automatically identified them as receiving 
methadone.  Service users described using the hatch to receive their methadone and going 
to the “normal people’s counter” to receive other medication.  Even when a service user was 
prescribed unsupervised consumption of methadone, discriminative practices might prevent 
them taking their ORT away from the pharmacy (Box 4, Participant 23). Service users were 
made to sign written agreements by the pharmacy. This was not done with other patient 
groups.  Participants described using two pharmacies: one to receive ORT and one to obtain 
their other medicines; to enable them to be treated as other patients were. 
The issue of time 
The issue of time was consistently raised; the time wasted in pharmacies waiting to receive 
methadone (Box 4, Participant 34). The use of restricted attendance times was felt to be a 
unfair (Box 4, Participant 40).  To complain about these arrangements risked getting put off 
the pharmacy list. This practice had real consequences and was used several times to 
explain why participants could not maintain employment.  The attendance pattern meant that 
employers could guess that their employee was on methadone.  The queue for methadone 
meant being brought into close proximity with undesirable people; drug dealers, people who 
might steal or create unpleasant situations. 
The issue of confidentiality 
Service users did not feel that their confidentiality was respected. Confidentiality in the 
pharmacy was undermined systematically: by the material and physical arrangements, by 
the procedures utilised to manage patients and through the actions and attitudes of staff 
members.  These arrangements were described by participants using words such as “the 
junkie door” and “segregation”.  Service users described how queuing to receive their 
methadone identified their reason for attendance to any onlooker. Participants related how 
staff members spoke about their consumption of methadone within hearing of other patients 
(Box 4, Participant 18). 
Positive experiences of care 
Participants readily described care which made a significant contribution to their well-being.  
An important and recurrent finding from this work was the value of being treated with dignity 
and respect.  Although focus group discussions always began with descriptions of poor 
experiences and difficult relationships, service users consistently spoke highly of “their 
pharmacist” and how the pharmacy they currently attended treated them well. 
There was good awareness of the nationally organised Minor Ailments Service 39, through 
which they could access a range of medication for free.  A variety of clinical interactions 
were described, from support with gestational diabetes to management of a traumatic wound 
(Box 4, Participant 20, Participant 26).  Where care was highly regarded, it was because 
positive relationships with staff were formed and maintained. 
Service users’ explanations for their experiences 
Participants could understand the way that people treated them like this.  The reasons arose 
from their own behaviours (for example shop-lifting), but also through the way they were 
forced to act through circumstances (experiences of stigma and discrimination) and the 
lifestyle they had adopted.  There was a perception of shared responsibility for their 
treatment, with an acknowledgement that some service users expected poor treatment and 
acted accordingly (Box 4 Participant 21).  The idea that a public face was assumed by the 
service user in order to protect their feelings was described several times.   
Making things better 
Participants expressed a desire to use the same consultation room as other pharmacy 
users, so that their care could be undertaken in private. It was acknowledged that the 
numbers of service users using pharmacies made this unlikely.  Participants recognised the 
poor behaviours of a few individuals but there was general resentment that this led to all 
service users being treated in the same way.  Focus group participants wished for the 
pharmacy service to operate more flexibly and responsively to their needs and support their 
process of recovery more actively. Participants described the wish to be treated as 
individuals rather than as a group. 
Discussion 
Main findings of this study  
Participants in this research describe the social context surrounding attendance at 
community pharmacies: how the assemblage of networks of actors interplays with pharmacy 
services.  Accounts demonstrate that people prescribed ORT are managed differently from 
other patients. Service users experience stigma and discrimination in pharmacies, other 
healthcare settings and generally in society. The organisation of care in pharmacies 
effectively denies service users confidentiality. 
Narratives about negative experiences were tempered by accounts of positive experiences 
of care. The discriminating factor between positive and negative experiences was that the 
service user was treated with dignity and respect.  Service users easily identify poor 
experiences but also valued positive relationships with their current pharmacy. 
What is already known on this topic? 
Perspectives on treatment recovery have been described by other researchers 20, 31, 40, 41, 42, 
43.  Evidence that service users are treated as an anti-social group has been reported 44 as 
has the detrimental consequences of pharmacy service organisation 26.   
Participants described a common experience of discrimination and stigmatisation when 
accessing routine healthcare 45, 46, 47. The parameters of stigma are well described 48.  The 
attitudes displayed by healthcare staff may mirror stigmatising attitudes across society 49.  
However, stigmatisation mitigates against recovery and continues the health inequalities 
experienced by this deprived and marginalised group 50, 51, 52. 
Most pharmacies in Scotland provide substance misuse services and many have created a 
separate facility for ORT supervision 53, 54.  This practice may enhance a stigmatised identity, 
especially when coupled with explicit discrimination and prejudicial attitudes of staff 22, 28.  
The use of waiting time to convey discrimination and create dependence is important 26, 27.  
The restrictions on access and consequences on employability are described in several 
places 45, 55.  Employment is a key step in addressing health inequalities and social inclusion 
56. 
That drug misusers often steal and how this affects their treatment has been reported 55.  A 
study of attitudes of community pharmacists reported that about ten percent of pharmacists 
had negative views 53. Work a decade later reported improved attitudes and increased 
service provision 21, 57 
What this study adds 
This most striking finding of this study is that despite 25 years of service provision, problems 
with ORT provision remain 53, 57.  Pharmacists may still be ill-prepared to manage difficult 
situations, when drug using clients behave aggressively or abusively, shoplift or are 
intoxicated 2.  The stigmatising attitudes experienced by service users are closely linked to 
policies on prohibition and criminalisation 49 
Limitations of this study 
This study draws on the qualitative insights of service users experiencing care within 
community pharmacies.  Use of a focus group methodology was clearly a viable method 
within the resource constraints of a public health needs assessment; however an 
ethnographic approach would contribute an alternative route to defining the effects of person 
place and time 58. 
The authors reflected that the strength of some contributions could have been influenced by 
the group dynamic; descriptions of poor experiences may have been better accepted 31, 32. 
The use of a female group was therefore undertaken, since male contributions were 
observed to dominate. We purposively recruited a group of experienced service users acting 
as peer mentors, to a final focus group and used this narrative to gain reaction to the 
findings and comment on themes 59. 
Conclusions 
Stigma, combined with a poor self image and apparent negative treatment may provoke 
negative behaviour and precipitate conflict 30. Pharmacists may be reluctant to deal with a 
group of clients who may sometimes be abusive or intoxicated and may shoplift 2. 
The social exclusion delivered through stigmatisation, mitigates against delivery of a 
recovery agenda for this multiply deprived and marginalised group 17. 
Capitalising on the contribution that community pharmacy can make requires further work to 
improve the quality of relationships with service users.  Service users have expressed the 
desire for more knowledgeable staff, capable of responding effectively to the issues that they 
bring 28.  It is likely that education and training as well as role support is required as well as 
steps to change organisational cultures within pharmacies in particular and healthcare in 
general 60.  This change however is within the current policy intention for modernising the 
delivery of pharmaceutical care from community pharmacy 61.  Further research is therefore 
required to confirm that a positive change in practice is achieved. 
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Table 1: Experiences and Views of People Using Pharmacies to Obtain a Methadone 
Prescription 
i. Tea, coffee provided to participants as they arrived. This allowed individuals to talk to 
each other and establish introductions 
ii. Participants were asked to introduce themselves and to say how they would like to be 
referred to. 
iii. The purpose and confidentiality of the research was explained and clarified, along with 
general guidance to ensure a good quality recording was made (i.e. not talking at the same 
time as others). 
iv. The following questions were used to guide the discussion, with sensitivity to the issues 
that were important to participants and also to the opportunity of each participant to 
contribute the issues and observations that were important to them. 
Questions Justification 
1. Can you tell me about your 
experiences of obtaining your 
methadone prescription from a 
pharmacy? 
a) How would you describe your 
relationship with the pharmacist? 
b) Do you feel you are treated with dignity 
and respect at all by your community 
pharmacy? 
c) What positive features of getting 
treatment at a pharmacy would you like 
to see more of? 
d) What negative features of getting 
treatment at a pharmacy would you like 
to see less of? 
 
General views on treatment of substance 
misusers in pharmacies 
Specific experiences of substance misusers 
in pharmacies 
2. Are you aware of having a care plan in 
place with regards to your methadone 
treatment? 
a) Has anyone discussed the content/its 
meaning? Have you received a copy of 
your care plan? Would you like to receive 
a copy of your care plan? 
b) Do you think such a care plan would 
improve your relationship with the 
pharmacist? 
c) What types of issues would be important 
to be discussed as part of the care plan? 
 
Making sense of the interaction with the 
pharmacist 
Establishing aspirations for the content of the 
service 
v. Group Finish: Participants were asked if there were further issues and observations that 
they had not been able to contribute. The facilitator gave a summary of the key points 




Table 2: Participant details 
  Number of Participants 
Age group at participation Less than 35 years 
35 – 44 years 
45 – 54 years 
Over 55 years 














Number recruited defined 
by sampling frame 
Large Urban Settlement 
Other Urban Settlement 
Accessible Rural Town 
Prison Educational Centre 
Women’s Group 












Box 1:  Strategies Employed to Ensure Rigour and Trustworthiness 
• Deviant cases were sought to falsify theory 
• Iterative data collection utilise to ensure emergent themes could be explored 
• A checking strategy was used within interviews to check interpretation 
• Data analysis was conducted by more than one team member 
 
  
Box 2- Themes Identified 
Theme 1 – The social context surrounding ORT users 
Theme 2 – The interaction with pharmacy service delivery 
Experience of stigma 
Experience of discrimination 
Issue of time 
Issue of confidentiality 
Positive Experiences of care 
Service Users Explanations for their Experiences 
Theme 3 – Making things better 
 
  
Box 3: The Social Context of ORT 
We are all shoplifters and we have all been stealing to feed wer drug habit.  See when you first get 
out the jail you don’t get paid for about a month, so, after 3 days you are skint.  Until about a month 
later you need to walk all the way into the toon, sometimes its 4 or 5 miles just to get your Meth, 
and then you have to walk home another 4 or 5 mile back or you can go shoplifting to get money for 
the buses or something.  Ken what, its just how it is and that’s how ye end up in the jail.  
Participant 20, Female 24 years. 
It does occupy…it occupies most of yir day and night coz yir always thinking aboot whar yir gona get 
money.  Participant 38, Male 37 years 
I thought it was a life saver at the start ken I thought it was great when I got on it and I got on it 
coz I thought it was another drug another charge and I wouldna wake up rattling.  I thought I’d get 
my methadone then I’d go score drugs like 2 fixes, 2 hits sometimes 3 or 4. 
That was my world, my hoose, the chemist and the boozer. Participant 40, Male 35 years 
You are keeping yourself to yourself, you just got outa the jail and you are keeping your head 
down.   You are not going out stealin but you are goin to that chemist.   You are taking that chance 
every day and you are seeing other drug users, right and it’s like, encouraging you.  You are likely 
doing it, in a minute.  First day out and you are pissed off an somebody offers you something that 
will be it.  Participant 16, Male 32 years 
And if they know you then thats even worse.  That’s how I moved to somewhere I’m not from 
where I dinna know anybody and do you know what it’s a hell of a lot better.  It’s so much better, I 
dinna get offered at the chemist cause no-one knows is.  So even though they see me going 
through that door because I dinna speak to anybody or give away anything its brilliant honestly.  I 
couldn’t have made a better choice for me and my son to go somewhere where they dinna know 
my past, they dinna know who I am, they don’t know what I’ve done do you know what I mean it’s 
brilliant.  Participant 18, Female 28 years 
A lot of people work that take methadone, a small majority, but they do and they want a normal 
life.  That’s how they are on methadone coz they want a normal life they widdnae be on 
methadone if they didnae want a normal life. 
Participant 33, Male 38 years 
 
  
Box 4: The Organisation of Pharmacy Methadone Services 
Experience of Stigma 
And I was on the bus the other day and it was an old couple were like “yeah all they junkies hanging 
about the chemist and it’s the ones who’ve got kids going in to that bit that I feel sorry for”  now they 
obviously didn’t know that they were talking to like a methadone user.  I felt like shit to be honest 
with you. Participant 18, Female 28 years 
Yeah because I mean you wouldnae treat somebody different if they were a, a diabetic and they 
were standing in front of you eating a sweetie, ken I mean you wouldnae say tae them you 
shouldnae be dain that (mumbles). What’s the difference between an addict and somebody that’s 
say self inflicted a lot of heart disease is self inflicted, there’s loads of things that are self inflicted so 
why dae they single out addicts or alcoholics. Participant 22, Male 37 years 
The Issue of Discrimination 
“If there is any more than two in the shop, if there are any more than two drug addicts in the shop, 
you have got to stand outside until one comes out. You are not allowed any more than two people in 
the pharmacy at the same time. It doesn’t matter if its rain, sleet or snow, you stand outside. She 
frankly told us that she doesn’t want us in there when there’s people in there”  
Participant 8, Male 32 years 
what I mean because it is embarrassing ken you’re standing there buzzing this buzzer and you’ve got 
to wait until they decide to pick up that phone and let you in so then there could be loads of people 
walking past you and you’re standing there ken they could clearly a’ ken that you’re going awa’ in 
there for that.  Know what I mean. Participant 20, Female 24 years 
First day she got methadone from the chemist she went tae take it oot the shop she went “thank 
you”.  “Oh hang on you need tae take that” she says “ah no I’m unsupervised” and the guy says “Oh 
no he says I don’t do that, as far as I’m concerned I don’t want methadone in the streets” 
Participant 23, Female 27 years 
The Issue of Time  
It’s only half an ‘oor, well the chemist I’m it you’ve got to go in efter half 9 in the morning right, you 
can go in at any time during the day.  But it’s other chemists, you go in, you’ve got to be in the 2 
‘oors and if you’re no there for 5 o’clock well in the efternane if you’re no there til 5 past 4 and 
you’re meant to be there by 4 you dinna get yir methadone.  That’s wrang. 
Participant 40, Male 35 years 
and some days I’d wait, wait, waiting, wait some mare.  I’d be waiting 15 minutes, 20 minutes, 25 
minutes in some cases until one day I got pig sick fed up o it coz I would see folk walking in from the 
doctors surgery and walking out before them walking in after them. I counted half a dozen folk one 
morning that walked in after the three o them and walked out before them with prescriptions in 
their hand.  Participant 34, Male 43 years 
The Issue of Confidentiality 
A couple of members of staff I would say are good but the rest of them nah, they look doon at you.  
I’d come off my methadone and went into rehab in November there and came off it and then I went 
into the chemist, but into the actual normal bit of the chemist and there was a prescription coming 
up from the DPC for a sleeping tablet ‘cause I wasn’t sleeping and when I went in the chemist was 
busy and the lady came over and she was like “could I help you” and I said yeah has a prescription 
come up from the DPC and she was like “what, for methadone?” right in front of everybody in that 
chemist.  And I looked at her, and they all knew what I’d just been through, and I’m looking, going, 
for methadone I dinnae think so, ken what I mean, and I was absolutely, I’d just couldnae believe 
that she’d done that.  Participant 18, Female 28 years 
Positive Experiences of care 
 I got bloods ta’en and they think I’ve got pregnancy diabetes so I went in and was telling the woman 
that just through conversation and she said maybe it was just something that I ate that day and I said 
nah a’ I had was, I had my methadone then I went right to the doctors to get the blood ta’en and she 
went well that could be what it was ‘cause methadone’s got that much sugar. 
Participant 20, Female 24 years 
Whan eh got stabbed Al  did gie me a lot of coz they didnae stitch it, they left it open and it wiz quiet 
a big wide wound, mind that ain in my groin and it was mair A  than the nurses coz eh wiz seeing her 
every day coz eh was only seeing meh doctors once a week and she wiz gieing me mair advice on 
how to keep it clean masel, dressings and this that and the next thing. So it was good. 
Participant 26, Male 32 years 
Service Users Explanations for their Experiences 
You’ve got a lot of drug addicts that are gonna go about with baggage and go “oh I’m an ex drug 
addict everybody’s looking down their nose at me”.  They’re gonna go about with that attitude and 
nine times out of ten they’re actually attracting that from people they may not have got it from coz 
they learn to protect themselves. But nine oot of ten because o the way they have been treated they 
go in wi that attitude because that’s the way that they have been treated”  
Participant 21, .Male 41 years 
 
  
Box 5: Making things better 
As I say I have no complaints about the pharmacy that I use.  They’re very good, there’s a little 
consulting room you can sit.  They take you into the consulting room you take your methadone and 
you leave, it’s all done in private.  If the consulting room’s busy they use a wee space they’ve got 
through the back but they always ask you very nicely if you don’t mind going through there.  So, 
they’re great. Participant 23, Female 27 years 
You don’t need anything else if you have got respect. If you get handed your methadone with a smile 
and asked how you are doing today. Participant 9, Male 38 years 
In the first instance its likely you would still need to go every day but then again I mean the medicine 
is there to support your recovery and so it is about how you move forward and it should be fitting 
into your life as well.  I mean the guys spoke earlier about they think it’s better that you need to go 
in every day because they remember the 80’s when the streets were awash with methadone and 
stuff like that but it is a medicine like any other medicine and you know as you recover and as you 
change you become much more confident then the medicine should, it shouldn’t hamper your 
recovery. Participant 32, Male 42 years 
 
